The U.S. Food and Drug Administration has approved Bimzelx (bimekizumab-bkzx) for the treatment of adults with ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Reaches Alignment with FDA Regarding Phase 3 Trial Plan On November 25, 2024, Imunon, Inc. (NASDAQ:IMNN) announced it had reached alignment with ...

FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment ...

Researchers discover that capillary obstruction in diabetes, triggered by elevated interleukin-10 signaling, may contribute to cognitive deficits independent of blood sugar levels. In a recent study ...

Mural Oncology (NASDAQ:MURA – Get Free Report) is one of 1,048 public companies in the “Pharmaceutical preparations” industry ...

A daily dose of vitamin B3 reduced inflammation in the lungs of patients with COPD, Danish researchers report. "T ...

Autoimmunity Biosolutions has closed a seed financing to support its work advancing a next-generation, immuno-corrective therapy for autoimmune diseases. The company’s approach targets a branch of the ...

Type 2 diabetes (T2D) and obesity (OB) are associated with chronic low-grade inflammation and increased fracture risk. In vitro studies showed that inflammation induces bone erosion and inhibits bone ...

Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF) ...

A new study suggests that nicotinamide riboside (a form of vitamin B3) may reduce lung inflammation in COPD patients, with ...

In the trial, 20% of patients didn’t respond well to the PCSK9 inhibitor—could genetic markers be used to tailor therapy?

Protagonist Therapeutics (PTGX) announced the selection of PN-881, an oral peptide interleukin-17, or IL-17, antagonist, as a development ...